TransMedics Group (NASDAQ:TMDX) Shares Up 8.8% – Here’s Why

TransMedics Group, Inc. (NASDAQ:TMDX) was up 8.8% during mid-day trading on Wednesday . The company traded as high as $128.02 and last traded at $127.3810. Approximately 323,007 shares changed hands during trading, a decline of 74% from the average daily volume of 1,223,270 shares. The stock had previously closed at $117.07.

Analyst Ratings Changes

Several equities analysts have recently issued reports on TMDX shares. Wall Street Zen upgraded TransMedics Group from a “hold” rating to a “buy” rating in a research report on Saturday, October 18th. Zacks Research cut TransMedics Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Jefferies Financial Group started coverage on TransMedics Group in a report on Monday, October 13th. They set a “buy” rating and a $145.00 target price on the stock. Stifel Nicolaus began coverage on shares of TransMedics Group in a research report on Thursday, September 4th. They issued a “hold” rating and a $115.00 price target on the stock. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of TransMedics Group in a report on Wednesday, October 8th. Seven investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $131.80.

TransMedics Group Trading Up 5.7%

The company has a debt-to-equity ratio of 1.43, a quick ratio of 7.13 and a current ratio of 7.69. The firm has a market capitalization of $4.47 billion, a P/E ratio of 53.01 and a beta of 2.05. The firm has a 50 day moving average price of $119.81 and a two-hundred day moving average price of $120.44.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Wednesday, October 29th. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.29. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.The company had revenue of $143.82 million for the quarter, compared to analyst estimates of $145.33 million. During the same period in the previous year, the firm earned $0.12 earnings per share. TransMedics Group’s revenue for the quarter was up 32.2% compared to the same quarter last year. TransMedics Group has set its FY 2025 guidance at EPS. On average, equities research analysts expect that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insider Buying and Selling

In other TransMedics Group news, Director Edward M. Basile sold 4,142 shares of the firm’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $130.45, for a total value of $540,323.90. Following the completion of the transaction, the director directly owned 2,866 shares in the company, valued at $373,869.70. This trade represents a 59.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

A number of large investors have recently made changes to their positions in the company. CWM LLC boosted its stake in TransMedics Group by 20.1% in the 1st quarter. CWM LLC now owns 925 shares of the company’s stock worth $62,000 after purchasing an additional 155 shares during the period. Victory Capital Management Inc. lifted its holdings in shares of TransMedics Group by 3.8% in the first quarter. Victory Capital Management Inc. now owns 8,365 shares of the company’s stock valued at $563,000 after purchasing an additional 308 shares in the last quarter. Allianz Asset Management GmbH purchased a new stake in shares of TransMedics Group in the first quarter valued at $343,000. Legato Capital Management LLC acquired a new stake in shares of TransMedics Group in the first quarter worth $332,000. Finally, Tempus Wealth Planning LLC grew its holdings in shares of TransMedics Group by 9.2% during the first quarter. Tempus Wealth Planning LLC now owns 6,058 shares of the company’s stock valued at $408,000 after buying an additional 508 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.